371P Palbociclib plus endocrine therapy in clinically relevant HR+/HER2- mBC subgroups: A real-world multicenter study
R. Buonaiuto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), C. De Angelis(Federico II University Hospital), Ferdinando Riccardi(Ospedale Antonio Cardarelli), G. Colantuoni(Azienda Ospedaliera S.Giuseppe Moscati), S. Parola(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), Cinzia Cardalesi(University of Naples Federico II), A. Caltavituro(Federico II University Hospital), R. Esposito(Federico II University Hospital), Mariateresa Giuliano(University of Naples Federico II), F.P. Mangiacotti(Federico II University Hospital), Martina Pagliuca(Institut Gustave Roussy), A. Longobardi(University of Naples Federico II), Fabiano Flauto(University of Naples Federico II)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282